Abstract #3832
Evaluation of the novel SPIO GEH121333 for monitoring changes in tumor vascularity and vascular permeability after anti-angiogenic treatment using susceptibility contrast and T1-mapping
Else Marie Huuse 1,2 , Jana Cebulla 2 , Dan E Meyer 3 , Karina Langseth 4 , Siver Andre Moestue 2 , and Tone Frost Bathen 2
1
Department of medical Imaging, St. Olavs
University Hospital, Trondheim, Norway,
2
MI
lab and Department of Circulation and Medical Imaging,
Norwegian University of Science and Technology,
Trondheim, Norway,
3
Biomedical
Imaging & Physiology Laboratory, GE Global Research
Center, Niskayuna, NY, United States,
4
GE
Healthcare AS, Oslo, Norway
Preclinical-phase iron oxide particles (GEH121333), with
a relatively large diameter and a high r1/r2 rate was
used for monitoring vascular response to bevacizumab
treatment in ovarian xenografts. Changes in T2 and T2*
relaxation rate was used for calculation marker for the
blood vessel density Q=
R2/(
R2*
2/3
)
and post contrast tissue T1 after clearance of iron
particles from the blood pool was used as a measure for
changed tumor vessel permeability. The results suggest
that the novel GEH121333 particles can be used to detect
vascular changes after anti-angiogenic therapy and that
their magnetic properties allow evaluation of changes
both in T1 and susceptibility imaging, attributable to
underlying changes in permeability and blood vessel
density, respectively.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
